Shravani Reddy, MD
Gastroenterology · Orange, CANPI 1861855686
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,664 of the $4,210 with a category attached, or 63.3%. 15 manufacturers reported payments, led by Steris Corporation at 45.6% of the total. 2025 is the largest year on record at $2,543, more than ten times the $68 reported in 2021.
Across 27 payments — averaging $155.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Steris Corporation$2K
- Medtronic$1K
- Regeneron$148
- Conmed Corporation$143
- Aimmune Therapeutics, Inc.$125
- Phathom Pharmaceuticals, Inc.$124
- plus $670 from 9 others
What the payments were for
- Travel & lodging$2,66463%
- Food & beverage$1,54637%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Steris Corporation | 7 | $1,920 |
| Medtronic | 6 | $1,080 |
| Regeneron | 1 | $148 |
| Conmed Corporation | 1 | $143 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $124 |
| AbbVie | 1 | $120 |
| Lilly USA, LLC | 1 | $118 |
| Boston Scientific | 2 | $114 |
| Mauna Kea Technologies, Inc. | 1 | $99 |
| Lucid Diagnostics Inc. | 1 | $92 |
| Sanofi | 1 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Olympus America Inc. | 1 | $15 |
| Endogastric Solutions, Inc | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,210 in reported general payments places this provider in the 65th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 13 | $5,251 |
| Dexlansoprazole DrDexlansoprazole | 17 | $3,464 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 152 | $3,194 |
| Pantoprazole Sodium | 33 | $903 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 14 | $821 |
| Lansoprazole | 13 | $638 |
| Omeprazole | 66 | $495 |
| Ondansetron OdtOndansetron | 16 | $492 |
| Famotidine | 25 | $162 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Orange
- Carl AlbersOrange$383K
- Jason SamarasenaOrange$330K
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.